epilepsy
Conditions
Interventions
Addition of verapamil to the epilepsy medciation of patients.
Sponsors
Stichting Epilepsie Instellingen Nederland
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: - patients aged 18 years and older with a history of localization-related epilepsy of at least 2 years; - epilepsy not controlled despite the (previous) use of two or more antiepileptic drugs; - current use of carbamazepine as an antiepileptic drug, with the possible addition of no more than one other antiepileptic drug; - seizure frequency of at least 2 seizures per month; - AED serum levels in therapeutic range
Exclusion criteria
Exclusion criteria: - There was no or an uncertain diagnosis of epilepsy, based on clinical history, seizure description and/or EEG registration. - progressive neurological disease - cardiac disease (heart failure; 2nd or 3rd degree atrioventricular block; sick sinus syndrome; Wolf-Parkinson-White syndrome; sinus bradycardia) - hypotension (defined as lower systolic pressure than 100 mm Hg and/or lower diastolic prerssure than 70 mm Hg) - pregnancy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Percentage of patients with more than 50% reduction in seizure frequency during the maintenance period compared to the baseline seizure frequency | — |
Secondary
| Measure | Time frame |
|---|---|
| - number of patients withdrawing from the study due to adverse effects - MDR1 expression in peripheral blood mononuclear cells prior and following verapamil administration | — |
Countries
Netherlands
Outcome results
None listed